2024
Identification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reports
2023
Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention
Lim J, Njei B. Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention. Hepatic Medicine Evidence And Research 2023, 15: 151-164. PMID: 37814605, PMCID: PMC10560482, DOI: 10.2147/hmer.s385133.Peer-Reviewed Original ResearchAcute liver injuryCOVID-19 patientsPre-existing chronic liver diseaseCOVID-19Chronic liver diseaseSARS-CoV-2Immune dysregulationSupportive careBiliary dysfunctionHepatic injuryLiver injuryVascular changesLiver diseaseClinical manifestationsSignificant complicationsLong-term effectsDiagnostic criteriaTherapeutic targetCholangiopathyDiagnostic advancementsPatientsGlobal healthCOVID-19 pandemicInjuryDiverse manifestationsScreening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ilagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNon-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseLiver diseaseCommon chronic liver diseaseNonalcoholic fatty liver diseaseCurrent expert guidelinesHigh-risk patientsChronic liver diseaseSteatotic liver diseaseClinical practice implicationsHepatic decompensationLiver biopsySociety guidelinesSpecialty referralsNovel therapiesExpert guidelinesLiver cancerDisease awarenessObesity epidemicSerum indicesClinical practiceScreening toolDiseaseDiagnosisExercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Chen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseEffects of exerciseFatty liver diseaseHistological outcomesLiver histologyLiver diseaseClinical trialsHistological endpointsSystematic reviewSignificant histopathological improvementNAFLD activity scoreImpact of exerciseIndependent effectsRandom-effects modelSystematic literature searchHistopathological improvementExercise interventionActivity scoreClinical endpointsPooled estimatesMeta-AnalysisTotal participantsLiterature searchComparison group
2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional studyAGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology 2022, 163: 764-774.e1. PMID: 35842345, PMCID: PMC9398982, DOI: 10.1053/j.gastro.2022.06.023.Peer-Reviewed Original ResearchConceptsLean Nonalcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseType 2 diabetes mellitusClinical Practice Updates CommitteeBiopsy-confirmed nonalcoholic steatohepatitisFatty liver diseaseBody mass indexDiabetes mellitusLean individualsLiver diseaseNonalcoholic steatohepatitisLean personsLiver cirrhosisMass indexHepatic steatosisNoninvasive testsManagement of NAFLDSodium-glucose cotransporter 2 inhibitorsGlucagon-like peptide-1 agonistsLysosomal acid lipase deficiencyPrognosis of NAFLDAGA Governing BoardLiver biochemical testsModest weight lossCotransporter 2 inhibitors
2020
Prevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited States
2018
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
Nguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCompensated liver diseaseLiver diseaseDisease severityCause inpatientLiver transplantHepatitis BHealthcare utilizationHepatocellular carcinomaHigh emergency department (ED) utilizationHighest mean annual costCause inpatient admissionsChronic hepatitis BDisease statesHealthcare resource utilizationLiver disease groupEmergency department utilizationEmergency room visitsHepatocellular carcinoma groupProgressive disease statesPharmaceutical utilizationMean annual costLiver disease statesProgressive diseaseHepatitis B.
2017
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2016
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American Journal Of Gastroenterology 2016, 112: 18. PMID: 27995906, DOI: 10.1038/ajg.2016.517.Peer-Reviewed Original ResearchMeSH KeywordsAlanine TransaminaseAlkaline PhosphataseAlpha 1-Antitrypsin DeficiencyAspartate AminotransferasesBilirubinBiopsyChemical and Drug Induced Liver InjuryCholestasisHemochromatosisHepatitis, AutoimmuneHepatitis, Viral, HumanHepatolenticular DegenerationHumansLiverLiver DiseasesLiver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseConceptsAbnormal liver chemistriesLiver chemistriesAlkaline phosphatase levelsAlanine aminotransferaseHepatocellular diseaseAspartate aminotransferaseALT levelsDisproportionate elevationHepatocellular injuryLiver diseasePhosphatase levelsElevated total serum bilirubin (TSB) levelsIU/Conjugated bilirubinNonalcoholic fatty liver diseaseTotal serum bilirubin levelsAlpha-1 antitrypsin deficiencyElevated conjugated bilirubinSerum conjugated bilirubinTotal bilirubin elevationLiver-related mortalityElevated alanine aminotransferasePrimary sclerosing cholangitisViral hepatitis AAlcoholic liver disease
2014
Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Re V. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients. Clinical Infectious Diseases 2014, 58: 1449-1458. PMID: 24569533, PMCID: PMC4001286, DOI: 10.1093/cid/ciu097.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusAdvanced hepatic fibrosisHuman immunodeficiency virusHepatitis C virusAlcohol use categoriesAlcohol-related diagnosesHIV/HCV-coinfected patientsHepatic fibrosisAlcohol consumptionNonhazardous drinkingBinge drinkingHIV/HCV groupAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireVeterans Aging Cohort StudyFIB-4 indexAging Cohort StudyCross-sectional studyHCV groupHCV statusHIV-InfectedUninfected participantsChronic hepatitisUninfected patientsCohort studyLiver disease
2009
Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
Garcia-Tsao G, Lim J. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. The American Journal Of Gastroenterology 2009, 104: 1802. PMID: 19455106, DOI: 10.1038/ajg.2009.191.Peer-Reviewed Original ResearchMeSH KeywordsCause of DeathDiagnostic ImagingDisease ProgressionEvidence-Based MedicineFemaleGastrointestinal HemorrhageHepatitis C, ChronicHepatorenal SyndromeHumansHypertension, PortalImmunohistochemistryLiver CirrhosisLiver FailureLiver Function TestsMaleRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexSurvival AnalysisUnited StatesUnited States Department of Veterans AffairsConceptsVariceal hemorrhageSevere complicationsHepatocellular carcinomaAcute variceal hemorrhageComplications of cirrhosisPresence of ascitesChronic liver diseaseSpontaneous bacterial peritonitisTreatment of ascitesRandomized clinical trialsTreatment of patientsStratification of patientsDifferent risk groupsQuality of lifeDecompensated patientsHepatorenal syndromeHepatitis CPortal hypertensionCirrhotic patientsProspective trialBacterial peritonitisHemodynamic alterationsLiver diseaseTreatment adherenceAscites formation